Comparison between Quadrant Future Tek IPO and Senores Pharmaceuticals IPO.
Quadrant Future Tek IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Senores Pharmaceuticals IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Quadrant Future Tek IPO is up to ₹290.00 Cr whereas the issue size of the Senores Pharmaceuticals IPO is up to ₹582.11 Cr. The final issue price of Quadrant Future Tek IPO is ₹290.00 per share and of Senores Pharmaceuticals IPO is ₹391.00 per share.
| Quadrant Future Tek IPO | Senores Pharmaceuticals IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹275.00 per share | ₹372.00 per share |
| Issue Price (Upper) | ₹290.00 per share | ₹391.00 per share |
| Issue Price (Final) | ₹290.00 per share | ₹391.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹0.00 per share | |
| Market Lot Size | 50 shares | 38 shares |
| Fresh Issue Size | 1,00,00,000 shares | 1,27,87,723 shares |
| Fresh Issue Size (Amount) | up to ₹290.00 Cr | up to ₹500.00 Cr |
| OFS Issue Size | 0 shares | 21,00,000 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹82.11 Cr |
| Issue Size Total | 1,00,00,000 shares | 1,48,87,723 shares |
| Issue Size Total (Amount) | up to ₹290.00 Cr | up to ₹582.11 Cr |
Quadrant Future Tek IPO opens on Jan 07, 2025, while Senores Pharmaceuticals IPO opens on Dec 20, 2024. The closing date of Quadrant Future Tek IPO and Senores Pharmaceuticals IPO is Jan 09, 2025, and Dec 24, 2024, respectively.
| Quadrant Future Tek IPO | Senores Pharmaceuticals IPO | |
|---|---|---|
| Anchor Bid Date | Jan 06, 2025 | Dec 19, 2024 |
| Issue Open | Jan 07, 2025 | Dec 20, 2024 |
| Issue Close | Jan 09, 2025 | Dec 24, 2024 |
| Basis Of Allotment (Tentative) | Jan 10, 2025 | Dec 26, 2024 |
| Initiation of Refunds (Tentative) | Jan 13, 2025 | Dec 27, 2024 |
| Credit of Share (Tentative) | Jan 13, 2025 | Dec 27, 2024 |
| Listing date (Tentative) | Jan 14, 2025 | Dec 30, 2024 |
| Anchor Lockin End date 1 | Feb 08, 2025 | Jan 24, 2025 |
| Anchor Lockin End date 2 | Apr 09, 2025 | Mar 25, 2025 |
Quadrant Future Tek IPO P/E ratio is 59.13, as compared to Senores Pharmaceuticals IPO P/E ratio of 39.77.
| Quadrant Future Tek IPO | Senores Pharmaceuticals IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 93.33 | 66.67 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 70 | 45.77 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 59.13 | 39.77 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹1160.00 Cr. | ₹1350.70 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 33.41% | 23.60% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 26.12% | 11.73% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.86 | 1.07 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹4.90 | ₹9.83 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 33.41% | 23.60% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Quadrant Future Tek IPO Retail Individual Investors (RII) are offered 10,00,000 shares while in Senores Pharmaceuticals IPO retail investors are offered 10,00,000 shares. Qualified Institutional Buyers (QIB) are offered 30,00,000 shares in Quadrant Future Tek IPO and 44,43,818 shares in Senores Pharmaceuticals IPO.
| Quadrant Future Tek IPO | Senores Pharmaceuticals IPO | |
|---|---|---|
| Anchor Investor Reservation | 45,00,000 shares | 66,65,725 shares |
| Market Maker Reservation | 0 shares | |
| QIB | 30,00,000 shares | 44,43,818 shares |
| NII | 15,00,000 shares | 22,21,908 shares |
| RII | 10,00,000 shares | 14,81,272 shares |
| Employee | 0 shares | 75,000 shares |
| Others | ||
| Total | 1,00,00,000 shares | 1,48,87,723 shares |
Quadrant Future Tek IPO subscribed 195.96x in total, whereas Senores Pharmaceuticals IPO subscribed 97.86x.
| Quadrant Future Tek IPO | Senores Pharmaceuticals IPO | |
|---|---|---|
| QIB (times) | 139.77x | 97.84x |
| NII (times) | 268.03x | 100.35x |
| Big NII (times) | 274.25x | 95.25x |
| Small NII (times) | 255.57x | 111.35x |
| RII (times) | 256.46x | 93.16x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 195.96x | 97.86x |
